MBX Biosciences (MBX) Cash & Equivalents (2023 - 2026)

MBX Biosciences has disclosed Cash & Equivalents across 4 years of filings, most recently posting $45.2 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $45.2 million, up 51.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $45.2 million (up 51.2% YoY), and the FY2025 annual result was $75.3 million, up 52.56% from the prior year.
• Cash & Equivalents came in at $45.2 million for Q1 2026 at MBX Biosciences, down from $75.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $223.1 million in Q3 2025 to a low of $29.9 million in Q1 2025.
• The 4-year median for Cash & Equivalents is $47.3 million (2024), against an average of $78.3 million.
• Across the five-year window, Cash & Equivalents soared 67.93% in 2025 and soared 51.2% in 2026, its largest moves.
• MBX Biosciences' Cash & Equivalents stood at $30.5 million in 2023, then soared by 61.68% to $49.4 million in 2024, then soared by 52.56% to $75.3 million in 2025, then sank by 39.95% to $45.2 million in 2026.
• The last three Cash & Equivalents figures came in at $45.2 million (Q1 2026), $75.3 million (Q4 2025), and $223.1 million (Q3 2025), per Business Quant data.